"10.1371_journal.pone.0087210","plos one","2014-02-10T00:00:00Z","Mickaël Terme; Mylène Dorvillius; Denis Cochonneau; Tanguy Chaumette; Wenhua Xiao; Mitchell B Diccianni; Jacques Barbet; Alice L Yu; François Paris; Linda S Sorkin; Stéphane Birklé","ATLAB Pharma, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France; INSERM U.892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France; CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, France; Department of Anesthesia, Mc Gill University, Montreal, Quebec, Canada; Department of Pediatrics, University of California San Diego, La Jolla, California, United States of America; Center of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan; Department of Anesthesiology, University of California San Diego School of Medicine, La Jolla, California, United States of America; Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France","Conceived and designed the experiments: MT MD DC LSS SB. Performed the experiments: MT MD DC WX SB TC. Analyzed the data: MT MD DC WX JB LSS SB. Contributed reagents/materials/analysis tools: MBD JB ALY. Wrote the paper: MT MD JB ALY FP LSS SB.","The authors have read the journal’s policy and have the following conflicts: At present, JB and SB are shareholders of ATLAB Pharma SAS and are inventors of a pending patent application regarding the use of ant-O-acetyl-GD2 monoclonal antibodies for cancer treatment. All other authors declare no conflict of interest. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials.","2014","02","Mickaël Terme","MT",11,TRUE,5,6,7,7,TRUE,TRUE,FALSE,0,NA,FALSE
